From bone to breast and back - the bone cytokine RANKL and breast cancer |
| |
| Authors: | Lorenz C Hofbauer Tilman D Rachner Christine Hamann |
| |
| Affiliation: | (1) Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Dresden Technical University Medical Center, Fetscherstr. 74, D-01307 Dresden, Germany;(2) Center of Regenerative Therapies Dresden, D-01307 Dresden, Germany;(3) Department of Orthopedics, Dresden Technical University Medical Center, Fetscherstr. 74, D-01307 Dresden, Germany |
| |
| Abstract: | Receptor activator of nuclear factor-κB ligand (RANKL) plays a pivotal role in regulating bone homeostasis. Osteoporosis and malignant bone disease secondary to breast cancer are characterized by enhanced RANKL production and increased bone turnover. Thus, denosumab, a monoclonal antibody to RANKL, has been developed and is now approved for various bone loss conditions. Recent results indicate that RANKL may also promote the development and osseous migration of breast cancer. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
